Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune DiseasesSAN FRANCISCO and VANCOUVER, British Columbia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the ”Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today unveiled JADE201, its investigational half-life extended, afucosylated monoclonal antibody targeting the B-cell activating factor receptor (BAFF-R). JADE201 is designed to overcome the limitations of current B cell-directed therapies by combining a dual mechanism of action and half-life extension technology, with the goal of improving on the clinical benefit of existing B-cell depleting therapies across a broad range of autoimmune diseases.
Jade Biosciences Announces $135 Million Private PlacementSAN FRANCISCO and VANCOUVER, British Columbia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $135 million to the Company, before placement agent fees and offering expenses.
Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA NephropathySAN FRANCISCO and VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has dosed the first cohort of participants in a Phase 1 healthy volunteer trial of JADE101. JADE101 is the Company’s investigational monoclonal antibody designed to selectively inhibit the activity of A PRoliferation-Inducing Ligand (APRIL) in patients with immunoglobulin A nephropathy (IgAN). The Company expects interim Phase 1 clinical data in the first half of 2026.
Jade Biosciences to Participate in Upcoming ConferencesSAN FRANCISCO and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences:
Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateSAN FRANCISCO and VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the quarter ending June 30, 2025, and provided a corporate update.
Jade Biosciences to Participate in Two Upcoming Investor ConferencesSAN FRANCISCO and VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in two upcoming investor conferences.
Jade Biosciences Appoints Brad Dahms as Chief Financial OfficerSAN FRANCISCO and VANCOUVER, British Columbia, July 01, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the appointment of Brad Dahms as Chief Financial Officer.
Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare ConferenceSAN FRANCISCO and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the Jefferies Global Healthcare Conference, June 3-5, 2025, in New York.
Jade Biosciences to Participate in TD Cowen’s 45th Annual Health Care Conference and Jefferies Biotech on the Beach SummitVANCOUVER, British Columbia and SAN FRANCISCO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in two upcoming investor conferences in March 2025:
Jade Biosciences to Participate in Upcoming Investor ConferencesVANCOUVER, British Columbia and SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Jade Biosciences (“Jade”), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that the company will participate in two upcoming investor conferences in November 2024.
Aerovate Therapeutics and Jade Biosciences Announce Merger AgreementMerger to create a company focused on advancing Jade Biosciences’ portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases
